irinotecan has been researched along with Ovarian Neoplasms in 173 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.58) | 18.7374 |
| 1990's | 28 (16.18) | 18.2507 |
| 2000's | 71 (41.04) | 29.6817 |
| 2010's | 66 (38.15) | 24.3611 |
| 2020's | 7 (4.05) | 2.80 |
| Authors | Studies |
|---|---|
| Alloatti, D; Badaloni, E; Cabri, W; Castorina, M; Giannini, G; Pisano, C; Vesci, L | 1 |
| Huang, R; Huang, X; Kong, J; Wang, H; Wang, M; Wang, Y; You, Q; Yu, C; Zhang, H | 1 |
| Chung, YM; Hu, MC; Khan, PP; Larrick, JW; Qiao, Y; Tsai, WB; Wang, H; Yu, B | 1 |
| Belogurov, AA; Chen, G; Chen, Z; He, Q; Li, X; Lin, S; Liu, Y; Tian, J; Yang, M; Zhang, F | 1 |
| Hatefi, A; Li, G; Nikkhoi, SK | 1 |
| Chen, Y; Luo, Y; Rong, P; Shi, C; Yang, B; Yang, J; Zhan, H; Zhang, S | 1 |
| Eguchi, S; Hara, K; Honjoh, H; Miyamoto, Y; Mori, M; Nara, K; Nishijima, A; Osuga, Y; Sone, K; Taguchi, A; Takada, T; Tojima, Y; Yamamoto, T | 1 |
| Goedken, M; Hatefi, A; Javidian, P; Louro, P; Malekshah, OM; Nomani, A; Patel, N; Polunas, M; Sarkar, S | 1 |
| Kato, K; Matsuoka, A; Nishikimi, K; Otsuka, S; Shozu, M; Takahashi, Y; Tate, S | 1 |
| Blaydorn, L; Coats, J; Farley, JH; Khemka, V; Lynch, CA; McGahey, K; Niu, J; Sangal, A; Waypa, J; Weiss, GJ | 1 |
| Chiba, Y; Fukagawa, D; Itamochi, H; Kawamura, H; Kojima-Chiba, A; Muraki, Y; Sato, S; Suga, Y; Sugai, T; Sugiyama, T; Yoshino, N | 1 |
| Bruckner, HW; Gurell, D; Hirschfeld, A | 1 |
| Hatefi, A; Malekshah, OM; Nomani, A; Patel, N; Sarkar, S | 1 |
| Diaz, LA; Hellmann, MD; Hu, ZI; O'Reilly, EM; Shia, J; Stadler, ZK; Vyas, M; Wolchok, JD | 1 |
| Arakawa, A; Itani, Y; Ito, K; Kawaguchi, R; Shiozaki, T; Tabata, T; Takeuchi, S; Toyoda, S; Tsubamoto, H | 1 |
| Enomoto, T; Fujita, M; Kimura, T; Kobayashi, E; Matsuzaki, S; Tsutsui, T; Ueda, Y; Yoshino, K | 1 |
| Boku, N; Fujiki, T; Fujino, K; Gemma, A; Kakihata, K; Masatani, S; Morita, S; Shiozawa, T; Tadokoro, J | 1 |
| Liu, JL; Palakurthi, S; Vangara, KK | 1 |
| Goto, S; Kamigaki, T; Saito, M; Yano, K | 1 |
| Furuya, K; Goto, T; Hirata, J; Horie, K; Kikuchi, Y; Kino, N; Kudoh, K; Takahashi, M; Takano, M; Yokota, H | 1 |
| Fujiwara, K; Katakami, N; Kitao, A; Matsumoto, K; Minami, H; Morita, S; Negoro, S; Shibata, N; Tanioka, M; Yamaguchi, S | 1 |
| Enomoto, T; Fujita, M; Kimura, T; Miyatake, T; Nagamatsu, M; Nishio, Y; Tsutsui, T; Ueda, Y; Yamasaki, M; Yoshino, K | 1 |
| Duvillard, P; Gouy, S; Lhomme, C; Morice, P; Pautier, P; Uzan, C | 1 |
| Burtness, B; Chun, YS; Cohen, SJ; Hall, MJ; Nagorney, DM; Sigurdson, ER; Thomay, AA; Truty, MJ | 1 |
| Boige, V; Borget, I; Caramella, C; Dromain, C; Ducreux, M; Dumont, F; Elias, D; Farron, M; Goéré, D; Honoré, C; Malka, D; Pottier, E | 1 |
| Bakrin, N; Cotte, E; Gilly, FN; Glehen, O; Passot, G; Roux, AS; Vaudoyer, D | 1 |
| Chaudhury, A; Chiu, GN; Liu, Y; Shaikh, IM; Tan, BJ; Tan, BM; Tan, KB | 1 |
| Ali, HI; Kolluru, S; Liu, JL; Lu, D; Palakurthi, S; Vangara, KK | 1 |
| Banville, M; Collins, C; Cruz-Muñoz, W; Di Desidero, T; Hashimoto, K; Jaramillo, ML; Kerbel, RS; Man, S; O'Connor-McCourt, MD; Xu, P | 1 |
| Hiotis, S; Jibara, G; Labow, DM; Romanoff, A; Sarpel, U; Shrager, B; Tabrizian, P; Yang, MJ | 1 |
| Fujimori, K; Kaido, Y; Kaiho, M; Mizunuma, H; Nishiyama, H; Omi, H; Otsuki, T; Shoji, T; Sugiyama, T; Takano, T; Takatori, E; Yaegashi, N; Yokoyama, Y | 1 |
| Hasegawa, K; Ichikawa, R; Kato, R; Kawamura, K; Oe, S; Torii, Y; Udagawa, Y | 1 |
| Hamasaki, T; Hisamatsu, T; Kawano, M; Kimura, T; Kishimoto, T; Mabuchi, S; Matsumoto, Y; Sasano, T; Sawada, K; Takahashi, K; Takahashi, R; Takahashi, T | 1 |
| Berek, JS; Chung, YM; Guan, M; Hu, MC; Hu, T; Ma, J; Ma, M | 1 |
| Asahara, H; Ishikawa, T; Itamochi, H; Kigawa, J; Kuroki, M; Manabe, S; Miyamoto, S; Miyata, K; Nam, SO; Odawara, T; Takada, S; Yotsumoto, F | 1 |
| Cho, H; Kim, JH; Kim, S; Kim, SW; Kim, YT; Lee, M; Nam, EJ | 1 |
| Kojima, A; Konishi, H; Nogawa, T; Okame, S; Shiroyama, Y; Takehara, K; Yamamoto, Y; Yokoyama, T | 1 |
| Kamura, T; Katsumata, N; Konishi, I; Matsumoto, K; Nakamura, K; Saitou, M; Satoh, T; Shibata, T; Takano, T; Yunokawa, M | 1 |
| Kamei, T; Miwa, I; Nakamura, Y; Sakamoto, Y; Shinagawa, M | 1 |
| Bai, H; Liu, Y; Ma, N; Ren, Z; Wang, F; Xu, S | 1 |
| Ding, YY; Song, LX; Xu, JF; Xu, Q | 1 |
| Fukagawa, S; Katsuda, T; Kondo, H; Maehara, M; Miyahara, D; Miyamoto, S; Miyata, K; Nam, SO; Ueda, T | 1 |
| Dartigues, P | 1 |
| Gjerset, RA; Zhao, M | 1 |
| Chen, H; Chen, X; Cheng, X; Gou, L; Li, W; Su, X; Wang, Y; Wei, X; Wei, Y; Wu, Y; Xie, Y; Yang, J; Yao, Y; Yu, L; Zhang, B; Zhang, H; Zhang, R; Zhang, Y | 1 |
| Auzolle, C; Bonnetain, F; Bouché, O; Brieau, B; Coriat, R; Ducreux, M; Goujon, G; Lecomte, T; Marthey, L; Pozet, A; Prieux, C; Rougier, P; Soibinet, P; Taieb, J; Tougeron, D; Zaanan, A | 1 |
| Chiba, Y; Chikumi, J; Harada, T; Itamochi, H; Komatsu, H; Kudoh, A; Nonaka, M; Oishi, T; Oumi, N; Sato, S; Shimada, M; Sugiyama, T | 1 |
| Alexandre, J; Aoki, D; Aotani, E; Enomoto, T; Fujiwara, K; Green, J; Hamano, T; Isonishi, S; Kato, K; Kim, BG; Kim, JW; Mikami, M; Nishino, K; Nomura, H; Okamoto, A; Pignata, S; Sugiyama, T; Suzuki, N; Tanabe, H; Terao, Y; Terauchi, F; Yaegashi, N; Yokoyama, Y; Yoshikawa, H | 1 |
| Blank, SV; Boyd, L; Curtin, J; Goldberg, JD; Li, X; Ling, HT; Muggia, F; Musa, F; Pothuri, B; Speyer, JL; Tiersten, A | 1 |
| Akahane, T; Aoki, D; Hirasawa, A; Kataoka, F; Mushiroda, T; Nanki, Y; Nomura, H; Susumu, N; Tominaga, E; Yamagami, W; Yoshihama, T | 1 |
| Fukai, H; Ichikawa, G; Kita, E; Kuwana, Y; Matsumoto, H; Nakayama, Y; Ohta, Y; Takami, M; Takimoto, T; Yamamoto, T | 1 |
| Kanazawa, T; Matsubara, M; Matsushita, K; Mukohara, Y; Nozaki, A; Oka, H; Tokumitsu, S; Tsunashima, T | 1 |
| Grènman, S; Miettinen, S; Ylikomi, T | 1 |
| Akira, S; Li, L; Tanaka, T; Umesaki, N; Yukawa, K | 1 |
| Fujiwara, K; Furuya, K; Goto, T; Hirata, J; Horie, K; Ishii, K; Kato, M; Kikuchi, Y; Kino, N; Kita, T; Sasaki, N; Takahashi, M; Takano, M; Yokota, H; Yoshikawa, T | 1 |
| Miettinen, S; Ylikomi, T | 1 |
| Amanze, A; Di Federico, E; Taylor, J; Verschraegen, C | 1 |
| Ishizuka, B; Kiguchi, K; Kobayashi, Y; Kondo, H; Ohara, T; Suzuki, N; Yahagi, N | 1 |
| Aoki, D; Inaba, N; Noda, K; Ochiai, K; Saito, T; Sugiyama, T; Takahashi, F; Takakura, S; Takano, M | 1 |
| Cruz-Munoz, W; Hashimoto, K; Kerbel, RS; Kumar, R; Man, S; Tang, T; Xu, P | 1 |
| Ajmi, S; Ben Ahmed, S; Ben Fatma, L; Ben Hadj Hamida, R; Braham, A; Chabchoub, I; Gahbiche, S; Gharbi, O; Hochlef, M; Landolsi, A; Letaief, R; Limam, S; Mokni, M | 1 |
| Choi, KC; Jeung, EB; Kim, KY; Kim, SU; Leung, PC | 1 |
| Mizutani, K; Nako, Y; Nei, T; Ozaki, Y; Wakana, K; Yasugi, T | 1 |
| Asami, S; Idani, F; Kin, H; Komoto, S; Kubo, S; Kubota, T; Kumano, K; Kurose, Y; Muro, M; Nojima, H; Sasaki, H; Takakura, N; Yoshioka, T | 1 |
| Fujimoto, T; Kumagai, S; Kurachi, H; Mizunuma, H; Nakahara, K; Nishiyama, H; Omi, H; Shoji, T; Sugiyama, T; Takano, T; Takatori, E; Tase, T; Yaegashi, N; Yokoyama, Y; Yoshizaki, A | 1 |
| Choi, YJ; Kim, JS; Kim, ST; Kim, YH; Oh, SC; Park, KH; Seo, JH; Shin, SW | 1 |
| Futagami, M; Hakamada, K; Hirakawa, H; Mizunuma, H; Yokoyama, Y | 1 |
| Chen, DY; Qi, Q; Zhao, WY | 1 |
| Fayad, W; Felth, J; Fryknäs, M; Glimelius, B; Graf, W; Gullbo, J; Hassan, S; Larsson, R; Laryea, D; Linder, S; Mahteme, H; Nygren, P; Påhlman, L; Rickardson, L | 1 |
| Ota, T; Takeshima, N; Takizawa, K | 1 |
| Kamura, T; Kuzuya, K; Noda, K; Ochiai, K; Sugiyama, T; Tamura, K; Ushijima, K | 1 |
| Enomoto, T; Fujita, M; Kimura, T; Kobayashi, E; Tsutsui, T; Ueda, Y; Yoshino, K | 1 |
| Enomoto, T; Fujita, M; Kimura, T; Kobayashi, E; Matsuzaki, S; Miyoshi, Y; Morimoto, A; Ueda, Y; Yokoyama, T; Yoshino, K | 1 |
| Fukuda, H; Kamura, T; Katsumata, N; Konishi, I; Matsumoto, K; Saito, I; Shibata, T | 1 |
| Huang, H; Li, H; Liu, JH | 1 |
| Iitsuka, C; Iwase, H; Nomura, H; Omatsu, K; Sakamoto, K; Takada, T; Takeshima, N; Takizawa, K | 1 |
| Aoki, D; Chiyoda, T; Kataoka, F; Nomura, H; Susumu, N; Tominaga, E; Tsuda, H; Yamagami, W | 1 |
| Kunito, S; Nagata, C; Ochiai, K; Okamoto, A; Saito, M; Sasaki, H; Takakura, S; Tanaka, T; Yamada, K; Yanaihara, N | 1 |
| Granot, T; Meruelo, D | 1 |
| Furuya, K; Goto, T; Kato, M; Kita, T; Kudoh, K; Miyamoto, M; Sasaki, N; Takano, M; Watanabe, A; Yoshikawa, T | 1 |
| Kaneda, N; Konishi, H; Kurita, A; Matsuzaki, T; Takagi, A | 1 |
| Gershenson, DM | 1 |
| Boven, E; Hausheer, FH; Pinedo, HM; Schlüper, HM; Van Hattum, AH | 2 |
| Hasegawa, K; Hiura, M; Ikeda, M; Ishikawa, M; Kamura, T; Kikkawa, F; Noda, K; Ochiai, K; Ohashi, Y; Saji, F; Sato, S; Sugiyama, T; Takahashi, T; Takeuchi, S; Umesaki, N; Yakushiji, M | 1 |
| Fujii, H; Konishi, M; Koshiyama, M; Tauchi, K; Yoshida, M | 1 |
| Kawano, Y; Miyakawa, I; Narahara, H; Nasu, K; Takai, N; Utsunomiya, H | 1 |
| Inoue, S; Kagawa, M; Kusanishi, H; Watanabe, Y | 1 |
| Bodurka, DC; Gano, J; Gershenson, DM; Kavanagh, JJ; Levenback, C; Wharton, JT; Wolf, JK | 1 |
| Kanishi, Y; Kiguchi, K; Kobayashi, Y; Kondo, H; Okuma, Y; Saito, K; Sato, S | 1 |
| Noda, K; Ochiai, K; Sugiyama, T; Yakushiji, M | 1 |
| Belinson, J; Markman, M; Rose, P; Webster, K; Zanotti, K | 1 |
| Ishihara, A; Nagao, K; Tanaka, H; Toyoda, N; Umekawa, T | 1 |
| Aghajanian, C; Dizon, DS; Hensley, M; Hummer, A; Leitao, MM; Sabbatini, P; Spriggs, DR; Venkatraman, E | 1 |
| Bukowski, R; Canetta, R; Ganapathi, R; Grabowski, D; Lee, F; Markman, M; Mekhail, T; Peck, R; Takigawa, N; Uyar, D | 1 |
| Arai, K; Horiguchi, S; Iwasaki, Y; Katayanagi, S; Matsumoto, H; Miyamoto, H; Nishioka, K; Takahashi, K; Yamaguchi, T | 1 |
| Akiyama, T; Doi, T; Hirata, K; Homma, H; Iyama, S; Kida, M; Kogawa, K; Mezawa, S; Murakami, K; Murase, K | 1 |
| Hirano, T; Kubo, H; Masaki, K; Ogura, H; Taoka, H; Terauchi, F; Yamamoto, Y | 1 |
| Belinson, J; Escobar, PF; Markman, M; Rose, P; Webster, K; Zanotti, K | 1 |
| Cammia, C; Croci, V; De Nicolao, G; Germani, M; Magni, P; Pesenti, E; Poggesi, I; Rocchetti, M; Simeoni, M | 1 |
| Isonishi, S; Niimi, S; Ochiai, K; Sasaki, H; Tanaka, T; Yasuda, M | 1 |
| Kishida, T; Komiyama, M; Mori, T; Noguchi, M; Noguchi, Y; Ohnishi, M; Sawaguchi, K; Yabushita, H | 1 |
| Boiocchi, M; Campagnutta, E; Cecchin, E; Corona, G; Martella, L; Russo, A; Toffoli, G | 1 |
| Hatae, M; Nakamura, T; Onishi, Y | 1 |
| Ichikawa, Y; Nishida, M; Tsunoda, H; Yoshikawa, H | 1 |
| Aoki, Y; Fujita, K; Kurata, H; Tanaka, K; Watanabe, M | 1 |
| Sugiyama, T | 1 |
| de Graaf, M; Gerritsen, WR; Giaccone, G; Haisma, HJ; Oosterhoff, D; Overmeer, RM; Pinedo, HM; van Beusechem, VW; van der Meulen, IH | 1 |
| Amikura, T; Aoki, Y; Fujita, K; Nishino, K; Obata, H; Sekine, M; Tanaka, K; Yahata, T | 1 |
| Fujiwara, Y; Kasamatsu, T; Katsumata, N; Tsunematsu, R; Yamada, T; Yamamoto, N; Yonemori, K | 1 |
| Akiba, Y; Hibi, T; Higuchi, H; Iizuka, H; Izumiya, M; Nagata, H; Takaishi, H; Yamagishi, Y | 1 |
| Balasubramanian, BN; Fairchild, CR; Jang, GR; Long, B; Marathe, PH; Monticello, TM; Rose, WC; Wall, ME; Wani, MC | 1 |
| Andoh, M; Fujiwara, Y; Katsumata, N; Kohno, T; Matsumoto, K; Shimizu, C; Yamanaka, Y; Yonemori, K | 1 |
| Chan, S; Clamp, AR; Cruickshank, D; Hindley, A; Jayson, GC; Ledermann, J; Mäenpää, J; Sorbe, B; Vasey, P; Welch, R; Wilkinson, PM | 1 |
| Duncan, J; McLeod, HL; Scheffer, GL; Scheper, RJ; Shannon, WD; Zhang, W | 1 |
| Bae, JM; Choi, IJ; Chun, JH; Kim, CG; Kim, HK; Kim, YW; Lee, JH; Lee, JS; Park, SR; Ryu, KW; Yu, MS | 1 |
| Baek, JH; Chae, YS; Cho, GJ; Choi, YJ; Chung, JS; Jeon, SB; Jung, HY; Kim, DH; Kim, JG; Lee, KB; Shin, HJ; Sohn, SK; Yu, W | 1 |
| Ishihara, A; Kihira, T; Nomura, Y; Tanaka, H | 1 |
| Ishiguro, A; Kudo, T; Mitobe, S; Munakata, M; Okada, R; Sakata, Y; Shitara, K; Tomioka, R; Yokoyama, S | 1 |
| Kigawa, J; Kikuchi, Y; Kuzuya, K; Moriya, T; Sagae, S; Sugiyama, T; Suzuki, M; Takano, M; Takeuchi, S; Tsuda, H; Udagawa, Y; Yaegashi, N | 2 |
| Brocheriou, I; Deray, G; Izzedine, H; Rixe, O | 1 |
| Kanamori, T; Kawashima, T; Murakami, H; Nakamura, Y | 1 |
| Jobo, T | 1 |
| Kamura, T; Kitagawa, R; Nishio, S; Shouji, T; Sugiyama, T; Ushijima, K; Yoshizaki, A | 1 |
| Fujiwara, S; Ino, K; Kajiyama, H; Kato, S; Kikkawa, F; Nakamura, S; Nawa, A; Shibata, K; Suzuki, K | 1 |
| Inagaki, D; Katayama, K; Oosawa, H; Shiraishi, R; Tanabe, H; Tani, K; Wada, H; Yasuda, S | 1 |
| Tanaka, T; Umesaki, N; Utsunomiya, H; Utsunomiya, T | 1 |
| Aulicino, C; Benedetti, V; Bucci, F; Carminati, P; De Cesare, M; Foderà, R; Penco, S; Pisano, C; Vesci, L; Zuco, V; Zunino, F | 1 |
| Herzog, TJ; Wethington, SL; Wright, JD | 1 |
| Atsumi, R; Hakusui, H; Okazaki, O | 1 |
| Funayama, Y; Isogai, Y; Kanzawa, F; Kuraishi, Y; Lee, YS; Nishio, K; Ogasawara, H; Ohira, T; Saijo, N | 1 |
| Eguchi, K; Kanzawa, F; Karato, A; Kubota, N; Nishio, K; Ohe, Y; Saijo, N; Sasaki, Y; Shinkai, T; Tamura, T | 1 |
| Furue, H | 1 |
| Hata, K; Higuchi, M; Kajino, T; Shibata, N | 1 |
| Terada, K | 1 |
| Sinha, BK; Wang, Z | 1 |
| Hasumi, K; Shimizu, Y; Umezawa, S | 3 |
| Hasuo, Y; Imaishi, K; Kataoka, A; Komai, K; Nishida, T; Ookura, N; Sugiyama, T; Ushijima, K; Yakushiji, M | 1 |
| Shimizu, Y | 1 |
| Koarai, N; Kobayashi, A; Sugizaki, N; Yamaguchi, M | 1 |
| Boven, E; Erkelens, CA; Jansen, WJ; Kolfschoten, GM; Pinedo, HM; Van Ark-Otte, J | 1 |
| Astoul, C; Ollitrault, N; Salvat, D | 1 |
| Fujimura, M; Fushiki, H; Hidaka, T; Hori, S; Izumi, R; Yamakawa, Y | 1 |
| Kolker, HJ; Loos, WJ; Ma, J; Maliepaard, M; Nooter, K; Schellens, JH; Stoter, G; Verweij, J | 1 |
| Kigawa, J; Nishida, T; Okura, N; Sugiyama, T; Terakawa, N; Ushijima, K; Yakushiji, M | 1 |
| Rosen, LS | 1 |
| Brown, R; McDonald, AC | 1 |
| O'meara, AT; Sevin, BU | 1 |
| de Jong, LA; Floot, BG; Maliepaard, M; Pluim, D; Ruevekamp-Helmers, MC; Schellens, JH; van Gastelen, MA; van Waardenburg, RC | 1 |
| Kigawa, J; Minagawa, Y; Oishi, T; Sugiyama, T; Takahashi, M; Terakawa, N; Yakushiji, M | 1 |
| Chen, AY; Choy, H; Rothenberg, ML | 1 |
| Adachi, S; Kanazawa, R; Koyama, K; Ogasawara, T; Shibahara, H; Takemura, T; Tsuji, Y; Yamasaki, N | 1 |
| Kamura, T; Sugiyama, T; Ushijima, K | 1 |
| Saltz, LB | 1 |
| Beijnen, JH; Jonker, JW; Maliepaard, M; Scheffer, GL; Schellens, JH; Scheper, RJ; Schinkel, AH; Smit, JW | 1 |
| Arimoto, Y; Hayashi, S; Komura, H; Kunishige, I; Okuno, Y; Otsuki, Y; Shimoya, K | 1 |
| Aoki, D; Komuro, Y; Kubota, T; Nozawa, S; Susumu, N; Udagawa, Y | 1 |
| Azevedo, P; Deavers, MT; Freedman, RS; Kavanagh, JJ; Kudelka, AP; Lu, K; Verschraegen, CF | 1 |
| Itamochi, H; Kigawa, J; Minagawa, Y; Terakawa, N | 1 |
| Aiba, K; Akaza, H; Blackledge, G; Boku, N; Ikeda, T; Isonishi, S; Kato, M; Kawai, K; Mikami, O; Ohashi, Y; Saeki, T; Saijo, N; Sone, S; Stribling, D; Tsukagoshi, S; Tsuruo, T | 1 |
| Fujimura, M; Fushiki, H; Izumi, R; Nakashima, A; Saito, S; Yuuki, H | 1 |
| Fukai, H; Idei, T; Matsumoto, H; Nakayama, Y; Ohta, H; Sakamoto, H; Satoh, K; Takami, M; Togo, Y; Yamamoto, T | 1 |
| Boyd, G; Cummings, J; Jodrell, DI; Macpherson, JS; Smith, G; Smyth, JF; Wolf, H | 1 |
| Kohno, T; Mizukami, H; Ozawa, K; Saga, Y; Sato, I; Suzuki, M; Urabe, M | 1 |
| Akeshima, R; Iba, T; Itamochi, H; Kamazawa, S; Kanamori, Y; Kigawa, J; Sultana, H; Terakawa, N | 1 |
| de Bruijn, P; Loos, WJ; Mathijssen, RH; Nooter, K; Sparreboom, A; Verweij, J | 1 |
| Fujiwara, Y; Nakagawa, K; Niimi, S; Nishio, K; Saijo, N; Sugimoto, Y; Terashima, Y; Yokoyama, S | 1 |
| Akiya, K; Dobashi, K; Fujimoto, S; Hasumi, K; Negishi, Y; Suzuki, M; Takeuchi, S; Tamaya, T; Tanaka, K; Terashima, Y | 1 |
| Noda, K; Ohkawa, T; Sekiba, K; Sugawa, T; Taguchi, T; Takamizawa, H; Takeda, Y; Takeuchi, S; Tamaya, T; Yakushiji, M | 1 |
| Chen, SC; Inoue, K; Itoh, Y; Ogawa, M; Shibata, H; Wang, Y | 1 |
17 review(s) available for irinotecan and Ovarian Neoplasms
| Article | Year |
|---|---|
[Peritoneal tumor pathology - case no. 3 : peritoneal well-differentiated papillary mesothelioma].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Carboplatin; Combined Modality Therapy; Cystadenofibroma; Diagnosis, Differential; Female; Fluorouracil; Humans; Hyperthermia, Induced; Infusions, Parenteral; Irinotecan; Leucovorin; Mesothelioma; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Organoplatinum Compounds; Ovarian Neoplasms; Ovariectomy; Oxaliplatin; Paclitaxel; Pemetrexed; Peritoneal Neoplasms | 2015 |
Irinotecan in epithelial ovarian cancer.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Enzyme Inhibitors; Female; Gastrointestinal Diseases; Humans; Irinotecan; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Topoisomerase I Inhibitors | 2002 |
Intermittent, repetitive administrations of irinotecan (CPT-11) reduces its side-effects.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma; Diarrhea; Drug Administration Schedule; Female; Humans; Irinotecan; Leukopenia; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Retrospective Studies; Treatment Outcome | 2002 |
Complete response to radiation therapy in a patient with chemotherapy-resistant ovarian clear cell adenocarcinoma.
Topics: Adenocarcinoma, Clear Cell; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Drug Resistance; Female; Humans; Irinotecan; Magnetic Resonance Imaging; Middle Aged; Ovarian Neoplasms; Paclitaxel; Retreatment | 2002 |
Japanese ovarian trials: focus on irinotecan.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Female; Humans; Irinotecan; Japan; Ovarian Neoplasms; United States; Women's Health | 2003 |
[Treatment of platinum-resistant ovarian cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials as Topic; DNA Damage; Docetaxel; Drug Resistance, Neoplasm; Etoposide; Female; Gynecologic Surgical Procedures; Humans; Irinotecan; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Taxoids; Treatment Outcome | 2004 |
[Second-line chemotherapy for recurrent ovarian cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclophosphamide; Docetaxel; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Irinotecan; Ovarian Neoplasms; Paclitaxel; Platinum; Taxoids | 2005 |
Key role of topoisomerase I inhibitors in the treatment of recurrent and refractory epithelial ovarian carcinoma.
Topics: Antineoplastic Agents; Camptothecin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Neoplasm Recurrence, Local; Ovarian Neoplasms; Topoisomerase I Inhibitors; Topotecan | 2008 |
7-Ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxy camptothecin: mechanism of resistance and clinical trials.
Topics: Amino Acid Sequence; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Survival; CHO Cells; Clinical Trials, Phase I as Topic; Cricetinae; DNA Topoisomerases, Type I; Drug Resistance; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Molecular Sequence Data; Neoplasms; Ovarian Neoplasms; Point Mutation; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 1994 |
[Irinotecan hydrochloride (CPT-11)].
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Female; Humans; Irinotecan; Leukemia L1210; Lung Neoplasms; Ovarian Neoplasms; Uterine Cervical Neoplasms | 1994 |
[Development of new anti-cancer agents in Europe].
Topics: Antineoplastic Agents; Camptothecin; Colonic Neoplasms; Europe; Female; France; Humans; Irinotecan; Japan; Lung Neoplasms; Ovarian Neoplasms; Uterine Cervical Neoplasms | 1996 |
Individualized chemotherapeutic regimen for each histological subtype of ovarian carcinoma.
Topics: Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Carcinoma, Endometrioid; Carcinoma, Transitional Cell; Cisplatin; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Mitomycin; Ovarian Neoplasms | 1997 |
[A case of solitary metastatic splenic tumor of ovarian carcinoma].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Drug Administration Schedule; Epirubicin; Female; Humans; Hysterectomy; Irinotecan; Ovarian Neoplasms; Splenectomy; Splenic Neoplasms | 1997 |
Irinotecan in lymphoma, leukemia, and breast, pancreatic, ovarian, and small-cell lung cancers.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Irinotecan; Leukemia; Lung Neoplasms; Lymphoma; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms | 1998 |
DNA topoisomerase I-targeting drugs as radiation sensitizers.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Cycle; Colonic Neoplasms; Combined Modality Therapy; DNA Damage; DNA Repair; DNA Topoisomerases, Type I; Enzyme Inhibitors; Female; Head and Neck Neoplasms; Humans; Irinotecan; Lung Neoplasms; Neoplasms; Ovarian Neoplasms; Radiation-Sensitizing Agents; Topotecan | 1999 |
[New regimens for the treatment of gynecologic cancers].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials, Phase II as Topic; Cyclophosphamide; Docetaxel; Drug Administration Schedule; Female; Humans; Irinotecan; Ovarian Neoplasms; Paclitaxel; Taxoids; Thrombocytopenia; Uterine Cervical Neoplasms | 2000 |
The role of topoisomerase I inhibitor in cisplatin-resistant ovarian cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; Female; HeLa Cells; Humans; Irinotecan; Ovarian Neoplasms; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 2001 |
37 trial(s) available for irinotecan and Ovarian Neoplasms
| Article | Year |
|---|---|
Tailored-dose chemotherapy with gemcitabine and irinotecan in patients with platinum-refractory/resistant ovarian or primary peritoneal cancer: a phase II trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Irinotecan; Ovarian Neoplasms; Platinum | 2021 |
A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus).
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Diarrhea; Docetaxel; Doxorubicin; Drug Eruptions; Fatigue; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasms; Ovarian Neoplasms; Paclitaxel; Pancreatic Neoplasms; Polyethylene Glycols; Sarcoma; Small Cell Lung Carcinoma; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine; Vomiting | 2017 |
Phase II study of carboplatin and weekly irinotecan combination chemotherapy in recurrent ovarian cancer: a Kansai clinical oncology group study (KCOG0330).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Camptothecin; Carboplatin; Carcinoma, Ovarian Epithelial; Female; Humans; Irinotecan; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms | 2013 |
UGT1A1 genotype-specific phase I and pharmacokinetic study for combination chemotherapy with irinotecan and cisplatin: a Saitama Tumor Board study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Middle Aged; Ovarian Neoplasms | 2013 |
A randomised, placebo-controlled, double-blind study of aprepitant in nondrinking women younger than 70 years receiving moderately emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Camptothecin; Carboplatin; Dexamethasone; Double-Blind Method; Drug Therapy, Combination; Endometrial Neoplasms; Female; Granisetron; Humans; Irinotecan; Logistic Models; Middle Aged; Morpholines; Neoplasms; Ovarian Neoplasms; Temperance; Treatment Outcome; Vomiting | 2013 |
A phase II study of combination chemotherapy using docetaxel and irinotecan for TC-refractory or TC-resistant ovarian carcinomas (GOGO-OV2 study) and for primary clear or mucinous ovarian carcinomas (GOGO-OV3 Study).
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Japan; Middle Aged; Ovarian Neoplasms; Paclitaxel; Prospective Studies; Taxoids | 2013 |
A phase I study of irinotecan and pegylated liposomal doxorubicin in recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 104 study).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Ovarian Epithelial; Doxorubicin; Female; Humans; Irinotecan; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Polyethylene Glycols | 2014 |
Phase II trial of oral etoposide plus intravenous irinotecan in patients with platinum-resistant and taxane-pretreated ovarian cancer (JCOG0503).
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Camptothecin; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Irinotecan; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Taxoids; Young Adult | 2015 |
Low-dose-intensity bevacizumab with weekly irinotecan for platinum- and taxanes-resistant epithelial ovarian cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum Compounds; Survival Rate; Taxoids; Treatment Outcome | 2015 |
The Safety of Pegylated Liposomal Doxorubicin Plus Irinotecan in Recurrent Ovarian Cancer Patients: A Phase I Trial.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Ovarian Epithelial; Doxorubicin; Female; Humans; Irinotecan; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Polyethylene Glycols; Treatment Outcome | 2015 |
Randomized Phase III Trial of Irinotecan Plus Cisplatin Compared With Paclitaxel Plus Carboplatin As First-Line Chemotherapy for Ovarian Clear Cell Carcinoma: JGOG3017/GCIG Trial.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Disease-Free Survival; Female; Humans; Irinotecan; Middle Aged; Ovarian Neoplasms; Paclitaxel; Survival Rate | 2016 |
Phase II study of irinotecan in combination with bevacizumab in recurrent ovarian cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Female; Humans; Irinotecan; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms | 2017 |
Randomized phase II trial of paclitaxel plus carboplatin therapy versus irinotecan plus cisplatin therapy as first-line chemotherapy for clear cell adenocarcinoma of the ovary: a JGOG study.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Female; Humans; Irinotecan; Middle Aged; Ovarian Neoplasms; Paclitaxel; Treatment Outcome | 2010 |
Phase II clinical study of the combination chemotherapy regimen of irinotecan plus oral etoposide for the treatment of recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 101 Group Study).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Camptothecin; Disease-Free Survival; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Irinotecan; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms; Survival Rate; Taxoids; Treatment Outcome | 2011 |
[Comparison between the effects of irinotecan or oxaliplatin combined with capecitabine in the treatment of advanced gastric cancer].
Topics: Adenocarcinoma; Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Diarrhea; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Neuritis; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Remission Induction; Stomach Neoplasms; Young Adult | 2011 |
Docetaxel/irinotecan combination chemotherapy in platinum/taxane-refractory and -resistant ovarian cancer: JGOG/WJGOG Intergroup Study.
Topics: Adult; Aged; Bridged-Ring Compounds; Camptothecin; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Irinotecan; Japan; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Platinum; Taxoids | 2013 |
Phase II study of oral etoposide and intravenous irinotecan for patients with platinum-resistant and taxane-pretreated ovarian cancer: Japan Clinical Oncology Group Study 0503.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Camptothecin; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Infusions, Intravenous; Irinotecan; Ovarian Neoplasms; Research Design; Taxoids | 2012 |
Irinotecan (CPT-11) and cisplatin as first-line chemotherapy for advanced ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Female; Humans; Irinotecan; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Prospective Studies; Treatment Outcome | 2002 |
Phase II trial of irinotecan in patients with metastatic epithelial ovarian cancer or peritoneal cancer.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Agents, Phytogenic; CA-125 Antigen; Camptothecin; Carcinoma, Papillary; Cystadenocarcinoma, Serous; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Immunoenzyme Techniques; Infusions, Intravenous; Irinotecan; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms | 2003 |
Toxicity associated with carboplatin/paclitaxel/Irinotecan use in advanced ovarian cancer: preliminary analysis.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Female; Humans; Irinotecan; Ovarian Neoplasms; Paclitaxel; Women's Health | 2003 |
Weekly docetaxel for patients with platinum/paclitaxel/irinotecan-resistant relapsed ovarian cancer: a phase I study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Camptothecin; Cisplatin; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Fatigue; Female; Humans; Infusions, Intravenous; Irinotecan; Maximum Tolerated Dose; Middle Aged; Ovarian Neoplasms; Paclitaxel; Taxoids; Treatment Outcome | 2003 |
Phase 2 trial of carboplatin, paclitaxel, and irinotecan in ovarian, fallopian tube, and primary peritoneal cancers.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Infusions, Intravenous; Irinotecan; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms | 2004 |
Combination chemotherapy with irinotecan hydrochloride (CPT-11) and mitomycin C in platinum-refractory ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Middle Aged; Mitomycin; Ovarian Neoplasms; Pilot Projects | 2004 |
Irinotecan hydrochloride (CPT-11) and mitomycin C as the first line chemotherapy for ovarian clear cell adenocarcinoma.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Female; Humans; Irinotecan; Middle Aged; Mitomycin; Ovarian Neoplasms; Prospective Studies | 2005 |
A phase I study and pharmacologic evaluation of irinotecan and carboplatin for patients with advanced ovarian carcinoma who previously received platinum-containing chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Female; Humans; Irinotecan; Maximum Tolerated Dose; Middle Aged; Ovarian Neoplasms | 2005 |
SCOTROC 2B: feasibility of carboplatin followed by docetaxel or docetaxel-irinotecan as first-line therapy for ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Carboplatin; Carcinoma; Disease Progression; Docetaxel; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Infusions, Intravenous; Irinotecan; Middle Aged; Ovarian Neoplasms; Peritoneal Neoplasms; Survival Analysis; Taxoids; Treatment Outcome | 2006 |
Phase II study of docetaxel and irinotecan combination chemotherapy in metastatic gastric carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Ovarian Neoplasms; Peritoneal Neoplasms; Stomach Neoplasms; Survival Rate; Taxoids | 2006 |
Phase II study of capecitabine and irinotecan combination chemotherapy in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Ovarian Neoplasms; Peritoneal Neoplasms; Stomach Neoplasms; Survival Rate | 2006 |
Salvage chemotherapy with a combination of irinotecan hydrochloride and mitomycin C in elderly Japanese patients with gynecological malignancies: a pilot study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Humans; Irinotecan; Japan; Mitomycin; Ovarian Neoplasms; Pilot Projects; Salvage Therapy; Uterine Cervical Neoplasms | 2006 |
Pilot study evaluating the efficacy and toxicity of irinotecan plus oral etoposide for platinum- and taxane-resistant epithelial ovarian cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Camptothecin; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Irinotecan; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Pilot Projects; Taxoids | 2007 |
[Successful treatment of clear cell adenocarcinoma of the ovary (OCCA) with a combination of CPT-11 and mitomycin C].
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Humans; Irinotecan; Middle Aged; Mitomycin; Ovarian Neoplasms; Remission Induction; Survival Rate | 1996 |
[Combination of irinotecan hydrochloride (CPT-11) and cisplatin as a new regimen for patients with advanced ovarian cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Cisplatin; Female; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Ovarian Neoplasms | 1996 |
Irinotecan (CPT-11) combined with cisplatin in patients with refractory or recurrent ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Administration Schedule; Female; Humans; Irinotecan; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms | 1998 |
A phase II study of combined CPT-11 and mitomycin-C in platinum refractory clear cell and mucinous ovarian carcinoma.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Irinotecan; Middle Aged; Mitomycin; Ovarian Neoplasms; Survival Rate; Time Factors | 1998 |
A pilot study of CPT-11 and cisplatin for ovarian clear cell adenocarcinoma.
Topics: Adenocarcinoma, Clear Cell; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Administration Schedule; Female; Humans; Irinotecan; Middle Aged; Ovarian Neoplasms; Pilot Projects | 1999 |
[A late phase II study of CPT-11 on uterine cervical cancer and ovarian cancer. Research Groups of CPT-11 in Gynecologic Cancers].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Drug Administration Schedule; Drug Evaluation; Female; Humans; Irinotecan; Leukopenia; Middle Aged; Ovarian Neoplasms; Uterine Cervical Neoplasms | 1991 |
[An early phase II study of CPT-11 in gynecologic cancers. Research Group of CPT-11 in Gynecologic Cancers].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Drug Administration Schedule; Drug Evaluation; Female; Humans; Irinotecan; Middle Aged; Ovarian Neoplasms; Uterine Neoplasms | 1991 |
119 other study(ies) available for irinotecan and Ovarian Neoplasms
| Article | Year |
|---|---|
Camptothecins in tumor homing via an RGD sequence mimetic.
Topics: Amino Acid Sequence; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Drug Delivery Systems; Female; Humans; Integrins; Male; Oligopeptides; Ovarian Neoplasms; Prostatic Neoplasms; Rats | 2012 |
Synthesis, mechanisms of action, and toxicity of novel aminophosphonates derivatives conjugated irinotecan in vitro and in vivo as potent antitumor agents.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Proliferation; Female; Humans; In Vitro Techniques; Irinotecan; Mice; Mice, Inbred BALB C; Mice, Nude; Organophosphonates; Ovarian Neoplasms; Topoisomerase I Inhibitors; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2020 |
Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.
Topics: Animals; Apoptosis; B7-H1 Antigen; Breast Neoplasms; Carcinoma, Hepatocellular; CD8-Positive T-Lymphocytes; Cell Proliferation; Female; Forkhead Box Protein O3; Gene Expression Regulation, Neoplastic; Humans; Immune Checkpoint Inhibitors; Immunotherapy; Irinotecan; Killer Cells, Natural; Liver Neoplasms; Mice; Mice, Inbred C57BL; Ovarian Neoplasms; Prognosis; Programmed Cell Death 1 Receptor; Topoisomerase I Inhibitors; Tumor Cells, Cultured; Tumor Microenvironment | 2021 |
SN-38 Sensitizes BRCA-Proficient Ovarian Cancers to PARP Inhibitors through Inhibiting Homologous Recombination Repair.
Topics: Adenosine Diphosphate Ribose; Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; DNA; Female; Humans; Irinotecan; Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Recombinational DNA Repair | 2022 |
Stem cell-assisted enzyme/prodrug therapy makes drug-resistant ovarian cancer cells vulnerable to natural killer cells through upregulation of NKG2D ligands.
Topics: Female; Fluorouracil; Humans; Irinotecan; Neoplasm Recurrence, Local; NK Cell Lectin-Like Receptor Subfamily K; Ovarian Neoplasms; Prodrugs; Stem Cells; Up-Regulation | 2023 |
Incidence and non-genetic risk factors of irinotecan-induced severe neutropenia in Chinese adult inpatients.
Topics: Adult; East Asian People; Female; Humans; Incidence; Inpatients; Irinotecan; Lung Neoplasms; Neutropenia; Ovarian Neoplasms; Retrospective Studies; Risk Factors | 2023 |
Heterogeneous effects of cytotoxic chemotherapies for platinum-resistant ovarian cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Ovarian Epithelial; Doxorubicin; Female; Gemcitabine; Humans; Irinotecan; Ovarian Neoplasms; Polyethylene Glycols | 2023 |
Bioengineered adipose-derived stem cells for targeted enzyme-prodrug therapy of ovarian cancer intraperitoneal metastasis.
Topics: Adipose Tissue; Animals; Antineoplastic Agents; Bioengineering; Carboxylesterase; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Enzyme Therapy; Female; Irinotecan; Mice, Nude; Molecular Targeted Therapy; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prodrugs; Stem Cells | 2019 |
Inhibition of Aurora Kinase A Synergistically Enhances Cytotoxicity in Ovarian Clear Cell Carcinoma Cell Lines Induced by Cisplatin: A Potential Treatment Strategy.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Aurora Kinase A; Biomarkers, Tumor; Camptothecin; Cell Line, Tumor; Cisplatin; Doxorubicin; Drug Synergism; Female; G2 Phase Cell Cycle Checkpoints; Humans; Immunohistochemistry; Irinotecan; Ki-67 Antigen; M Phase Cell Cycle Checkpoints; Middle Aged; Ovarian Neoplasms; Paclitaxel; Prognosis; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Tissue Array Analysis | 2017 |
Bevacizumab Added to Moderate-dose Chemotherapy for Refractory Uterine Cancer.
Topics: Adenocarcinoma; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bile Duct Neoplasms; Camptothecin; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Docetaxel; Endometrial Neoplasms; Female; Fluorouracil; Gemcitabine; Humans; Induction Chemotherapy; Irinotecan; Leucovorin; Middle Aged; Ovarian Neoplasms; Retrospective Studies; Taxoids | 2018 |
A novel chemotherapeutic protocol for peritoneal metastasis and inhibition of relapse in drug resistant ovarian cancer.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Irinotecan; Mice; Neoplastic Stem Cells; Oligopeptides; Ovarian Neoplasms; Peritoneal Neoplasms; Spheroids, Cellular; Treatment Outcome; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2018 |
Acquired resistance to immunotherapy in MMR-D pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Camptothecin; Drug Resistance, Neoplasm; Endometrial Neoplasms; Female; Fluorouracil; Humans; Immunotherapy; Indoleamine-Pyrrole 2,3,-Dioxygenase; Irinotecan; Leucovorin; Middle Aged; Ovarian Neoplasms; Oxaliplatin; Pancreatic Neoplasms | 2018 |
Taxane-sensitivity of ovarian carcinomas previously treated with paclitaxel and carboplatin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Taxoids | 2013 |
Risk factors for severe adverse effects and treatment-related deaths in Japanese patients treated with irinotecan-based chemotherapy: a postmarketing survey.
Topics: Aged; Analysis of Variance; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Asian People; Breast Neoplasms; Camptothecin; Colorectal Neoplasms; Death; Diarrhea; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Irinotecan; Japan; Leukopenia; Logistic Models; Lung Neoplasms; Lymphoma; Male; Middle Aged; Neoplasms; Ovarian Neoplasms; Product Surveillance, Postmarketing; Risk Assessment; Risk Factors; Sex Factors; Skin Neoplasms; Stomach Neoplasms; Thrombocytopenia | 2013 |
Hyaluronic acid-decorated PLGA-PEG nanoparticles for targeted delivery of SN-38 to ovarian cancer.
Topics: Animals; Biological Transport; Camptothecin; Cell Line, Tumor; CHO Cells; Cricetinae; Drug Carriers; Emulsions; Female; Humans; Hyaluronan Receptors; Hyaluronic Acid; Irinotecan; Nanoparticles; Ovarian Neoplasms; Particle Size; Polyethylene Glycols; Polyglactin 910; Topoisomerase I Inhibitors | 2013 |
A patient with scirrhous stomach cancer treated with combination of hyperthermotherapy and 5-aminolevulinic acid (ALA).
Topics: Adenocarcinoma, Scirrhous; Adult; Aminolevulinic Acid; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Signet Ring Cell; Cisplatin; Combined Modality Therapy; Dichloroacetic Acid; Docetaxel; Drug Combinations; Drug Therapy, Combination; Female; Humans; Hyperthermia, Induced; Irinotecan; Ovarian Neoplasms; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Photosensitizing Agents; Prognosis; Silicates; Stomach Neoplasms; Taxoids; Tegafur; Titanium | 2013 |
Results of oxaliplatin-based hyperthermic intraperitoneal chemotherapy in recurrent ovarian granulosa cell tumors.
Topics: Adult; Antineoplastic Agents; Camptothecin; Female; Granulosa Cell Tumor; Humans; Hyperthermia, Induced; Infusions, Parenteral; Irinotecan; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Retrospective Studies; Treatment Outcome | 2013 |
Modern chemotherapy mitigates adverse prognostic effect of regional nodal metastases in stage IV colorectal cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Hepatectomy; Humans; Irinotecan; Kaplan-Meier Estimate; Liver Neoplasms; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Young Adult | 2014 |
Prognostic significance of visible cardiophrenic angle lymph nodes in the presence of peritoneal metastases from colorectal cancers.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Digestive System Surgical Procedures; Female; Humans; Hyperthermia, Induced; Infusions, Parenteral; Irinotecan; Kaplan-Meier Estimate; Liver Neoplasms; Lymph Nodes; Male; Mediastinum; Middle Aged; Multivariate Analysis; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Peritoneal Neoplasms; Predictive Value of Tests; Prognosis; Retrospective Studies; Tomography, X-Ray Computed | 2013 |
Quality of life after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy: a prospective study of 216 patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Cisplatin; Cohort Studies; Colorectal Neoplasms; Combined Modality Therapy; Female; Humans; Hyperthermia, Induced; Irinotecan; Male; Mesothelioma; Middle Aged; Mitomycin; Neoplasms, Multiple Primary; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Peritoneal Neoplasms; Peritoneum; Prospective Studies; Pseudomyxoma Peritonei; Quality of Life; Stomach Neoplasms; Treatment Outcome | 2014 |
Liposome co-encapsulation of synergistic combination of irinotecan and doxorubicin for the treatment of intraperitoneally grown ovarian tumor xenograft.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Doxorubicin; Drug Synergism; Female; Humans; Irinotecan; Liposomes; Manganese; Mice; Mice, SCID; Ovarian Neoplasms; Ovary | 2013 |
SN-38-cyclodextrin complexation and its influence on the solubility, stability, and in vitro anticancer activity against ovarian cancer.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Cyclodextrins; Female; Humans; Irinotecan; Ovarian Neoplasms; Solubility | 2014 |
Analysis of acquired resistance to metronomic oral topotecan chemotherapy plus pazopanib after prolonged preclinical potent responsiveness in advanced ovarian cancer.
Topics: Administration, Metronomic; Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Indazoles; Inhibitory Concentration 50; Irinotecan; Mice, SCID; Neoplasm Metastasis; Neoplasm Staging; Ovarian Neoplasms; Pyrimidines; Sulfonamides; Topotecan; Treatment Outcome | 2014 |
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis: outcomes from a single tertiary institution.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Blood Transfusion; Camptothecin; Carcinoma; Colorectal Neoplasms; Combined Modality Therapy; Cytoreduction Surgical Procedures; Female; Gallbladder Neoplasms; Humans; Hyperthermia, Induced; Intraoperative Care; Irinotecan; Male; Middle Aged; Mitomycin; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Peritoneal Neoplasms; Pseudomyxoma Peritonei; Stomach Neoplasms; Survival Rate; Tertiary Care Centers | 2014 |
Retrospective comparative study of irinotecan and pegylated liposomal doxorubicin for platinum-resistant or -refractory epithelial ovarian and primary peritoneal carcinoma.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Middle Aged; Neoplasms, Glandular and Epithelial; Neutropenia; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum; Polyethylene Glycols; Retrospective Studies; Salvage Therapy; Treatment Outcome | 2014 |
Combination treatment with trabectedin and irinotecan or topotecan has synergistic effects against ovarian clear cell carcinoma cells.
Topics: Adenocarcinoma, Clear Cell; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Camptothecin; Cell Proliferation; Cisplatin; Dioxoles; Doxorubicin; Drug Resistance, Neoplasm; Drug Synergism; Everolimus; Female; Humans; Irinotecan; Ovarian Neoplasms; Paclitaxel; Sirolimus; Tetrahydroisoquinolines; Topotecan; Trabectedin; Tumor Cells, Cultured | 2014 |
Reprogramming ovarian and breast cancer cells into non-cancerous cells by low-dose metformin or SN-38 through FOXO3 activation.
Topics: Active Transport, Cell Nucleus; Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA Damage; Female; Forkhead Box Protein O3; Forkhead Transcription Factors; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Histones; Irinotecan; Metformin; Mice, Nude; Neoplastic Stem Cells; Ovarian Neoplasms; Phosphorylation; Protein Processing, Post-Translational; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
Contribution of transcription factor, SP1, to the promotion of HB-EGF expression in defense mechanism against the treatment of irinotecan in ovarian clear cell carcinoma.
Topics: Adenocarcinoma, Clear Cell; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Heparin-binding EGF-like Growth Factor; Humans; Irinotecan; Ovarian Neoplasms; Promoter Regions, Genetic; Protein Binding; Sp1 Transcription Factor | 2014 |
ATP-based chemotherapy response assay in primary or recurrent ovarian and peritoneal cancer.
Topics: Adenocarcinoma, Clear Cell; Adenosine Triphosphate; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Humans; Ifosfamide; Irinotecan; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Predictive Value of Tests; Sensitivity and Specificity; Taxoids | 2014 |
[A case of platinum-resistant, recurrent ovarian clear cell adenocarcinoma successfully treated with irinotecan (CPT-11) and paclitaxel (PTX) chemotherapy].
Topics: Adenocarcinoma, Clear Cell; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Ovarian Neoplasms; Paclitaxel; Platinum; Recurrence | 2014 |
Case of pure ovarian squamous cell carcinoma resistant to combination chemotherapy with paclitaxel and carboplatin but responsive to monotherapy with weekly irinotecan.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Squamous Cell; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Ovarian Neoplasms; Paclitaxel; Retreatment; Treatment Outcome | 2015 |
Correlation of UGT1A1 and ERCC1 gene polymorphisms with the outcome of combined irinotecan plus cisplatin treatment in recurrent ovarian cancer.
Topics: Adult; Aged; Alleles; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Ovarian Epithelial; Cisplatin; Diarrhea; DNA-Binding Proteins; Endonucleases; Female; Gene Expression; Gene Frequency; Genotype; Glucuronosyltransferase; Heterozygote; Homozygote; Humans; Irinotecan; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Polymorphism, Genetic; Treatment Outcome | 2015 |
Topoisomerase-I PS506 as a Dual Function Cancer Biomarker.
Topics: Amino Acid Sequence; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Colonic Neoplasms; DNA Topoisomerases, Type I; Female; Gene Expression; Humans; Irinotecan; Lung; Lung Neoplasms; Molecular Sequence Data; Neoplasms; Ovarian Neoplasms; Phosphorylation; Serine; Topotecan | 2015 |
Synthesis, characterization and targeting chemotherapy for ovarian cancer of trastuzumab-SN-38 conjugates.
Topics: Animals; Camptothecin; Cell Line, Tumor; Female; Humans; Immunoconjugates; Irinotecan; Mice; Mice, Inbred BALB C; Ovarian Neoplasms; Receptor, ErbB-2; Trastuzumab; Xenograft Model Antitumor Assays | 2015 |
Efficacy of modern chemotherapy and prognostic factors in patients with ovarian metastases from gastric cancer: A retrospective AGEO multicentre study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Camptothecin; Cisplatin; Epirubicin; Female; Fluorouracil; France; Humans; Irinotecan; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Middle Aged; Multivariate Analysis; Ovarian Neoplasms; Ovariectomy; Prognosis; Proportional Hazards Models; Retrospective Studies; Stomach Neoplasms; Taxoids; Tomography, X-Ray Computed; Treatment Outcome; Young Adult | 2016 |
Establishment and characterization of a novel ovarian clear cell carcinoma cell line, TU-OC-2, with loss of ARID1A expression.
Topics: Adenocarcinoma, Clear Cell; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Chromosomes; Cisplatin; DNA-Binding Proteins; Drug Resistance, Neoplasm; Female; Gene Deletion; Gene Expression; Humans; Irinotecan; Nuclear Proteins; Ovarian Neoplasms; Paclitaxel; Signal Transduction; Transcription Factors | 2016 |
UGT1A1 polymorphism as a prognostic indicator of stage I ovarian clear cell carcinoma patients treated with irinotecan.
Topics: Adult; Antineoplastic Agents, Phytogenic; Camptothecin; Disease-Free Survival; Female; Genetic Predisposition to Disease; Glucuronosyltransferase; Humans; Irinotecan; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Polymorphism, Genetic; Prognosis | 2017 |
[A case of brain metastasis from advanced ovarian clear-cell carcinoma during maintenance chemotherapy with irinotecan+cisplatin].
Topics: Adenocarcinoma, Clear Cell; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Cisplatin; Female; Humans; Irinotecan; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Radiography | 2008 |
[A case of ovarian cancer in which a remarkable effect was seen with intrathoracic administration of CDDP and CPT-11].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Female; Humans; Injections; Irinotecan; Middle Aged; Ovarian Neoplasms; Thorax; Tomography, X-Ray Computed | 2008 |
Inhibition of P-glycoprotein-mediated docetaxel efflux sensitizes ovarian cancer cells to concomitant docetaxel and SN-38 exposure.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Camptothecin; Cell Line, Tumor; Docetaxel; Drug Administration Schedule; Drug Interactions; Drug Resistance, Neoplasm; Female; G2 Phase; Gene Expression Regulation; Humans; Irinotecan; Ovarian Neoplasms; Taxoids | 2009 |
Irinotecan-induced ovarian follicular apoptosis is attenuated by deleting the kinase domain of death-associated protein kinase.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Calcium-Calmodulin-Dependent Protein Kinases; Camptothecin; Death-Associated Protein Kinases; Fas Ligand Protein; Female; Gene Deletion; Gene Expression Regulation, Neoplastic; Granulosa Cells; Humans; Irinotecan; Mice; Mice, Inbred C57BL; Models, Biological; Ovarian Follicle; Ovarian Neoplasms; Ovary | 2009 |
Clinical significance of UDP-glucuronosyltransferase 1A1*6 for toxicities of combination chemotherapy with irinotecan and cisplatin in gynecologic cancers: a prospective multi-institutional study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Polymorphism, Genetic; Prognosis; Prospective Studies; Risk Factors; Treatment Outcome; Uterine Cervical Neoplasms; Young Adult | 2009 |
Concomitant exposure of ovarian cancer cells to docetaxel, CPT-11 or SN-38 and adenovirus-mediated p53 gene therapy.
Topics: Adenocarcinoma; Adenoviridae; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Cycle; Combined Modality Therapy; Docetaxel; Female; Gene Expression Regulation, Neoplastic; Genetic Therapy; Genetic Vectors; Humans; Irinotecan; Ovarian Neoplasms; Taxoids; Tumor Suppressor Protein p53 | 2009 |
Irinotecan use during pregnancy.
Topics: Adult; Antineoplastic Agents, Phytogenic; Camptothecin; Colonic Neoplasms; Female; Humans; Irinotecan; Krukenberg Tumor; Ovarian Neoplasms; Pregnancy; Pregnancy Complications, Neoplastic; Prenatal Care | 2009 |
[Usefulness of clinical study of irinotecan and cisplatin for recurrent ovarian cancer].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Female; Humans; Irinotecan; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms | 2009 |
Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer.
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Cyclophosphamide; Dose-Response Relationship, Drug; Endothelial Cells; Female; Humans; Indazoles; Irinotecan; Mice; Mice, SCID; Neovascularization, Pathologic; Ovarian Neoplasms; Pyrimidines; Sulfonamides; Topotecan; Xenograft Model Antitumor Assays | 2010 |
[Prognostic factors and survival of metastatic colorectal cancer in the Sousse University Hospital (Tunisia): comparative study of two treatment period of 200 patients].
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Ovarian Neoplasms; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Survival Rate; Tunisia; Young Adult | 2010 |
Influence of the prodrugs 5-fluorocytosine and CPT-11 on ovarian cancer cells using genetically engineered stem cells: tumor-tropic potential and inhibition of ovarian cancer cell growth.
Topics: Animals; Antimetabolites; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line; Cell Line, Tumor; Cytosine Deaminase; Female; Flucytosine; Genes, Transgenic, Suicide; Genetic Engineering; Genetic Therapy; Genetic Vectors; Humans; Irinotecan; Mice; Ovarian Neoplasms; Prodrugs; Stem Cells | 2010 |
Successful surgical treatment and chemotherapy for ovarian cancer in a patient with idiopathic thrombocytopenic purpura.
Topics: Adenocarcinoma, Clear Cell; Camptothecin; Female; Humans; Irinotecan; Middle Aged; Ovarian Neoplasms; Postoperative Period; Purpura, Thrombocytopenic, Idiopathic | 2011 |
[A long-term survival case of bilateral ovarian metastasis of progressive gastric cancer treated by chemotherapy].
Topics: Adenocarcinoma, Scirrhous; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Docetaxel; Drug Combinations; Female; Gastrectomy; Humans; Irinotecan; Krukenberg Tumor; Ovarian Neoplasms; Ovariectomy; Oxonic Acid; Stomach Neoplasms; Taxoids; Tegafur | 2010 |
Capecitabine monotherapy as salvage treatment after failure of chemotherapy containing oxaliplatin and irinotecan in patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Capecitabine; Child; Child, Preschool; Colorectal Neoplasms; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Infant; Irinotecan; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Peritoneal Neoplasms; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome; Young Adult | 2011 |
[Successful optimal debulking surgery following chemotherapy combined with irinotecan hydrochloride and cisplatin for advanced clear cell carcinoma of the ovary].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Combined Modality Therapy; Female; Humans; Irinotecan; Middle Aged; Ovarian Neoplasms; Positron-Emission Tomography; Tomography, X-Ray Computed | 2011 |
Novel activity of acriflavine against colorectal cancer tumor cells.
Topics: Acriflavine; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Screening Assays, Antitumor; Female; Fluorouracil; High-Throughput Screening Assays; Humans; Irinotecan; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 2011 |
Second-line chemotherapy for carboplatin/paclitaxel-refractory ovarian cancer: are multi-agent chemotherapies of little value truly?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Irinotecan; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Taxoids | 2011 |
Salvage chemotherapy for recurrent or persistent clear cell carcinoma of the ovary: a single-institution experience for a series of 20 patients.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Ovarian Epithelial; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Retrospective Studies; Salvage Therapy; Survival Rate; Taxoids | 2013 |
Salvage chemotherapy for ovarian carcinoma recurring during or after consolidation chemotherapy with paclitaxel.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Cisplatin; Disease-Free Survival; Female; Humans; Irinotecan; Middle Aged; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Salvage Therapy; Time Factors; Treatment Outcome | 2011 |
[Study of irinotecan-induced toxicity and its correlation to UGT1A1 gene promoter polymorphisms].
Topics: Adult; Alleles; Amplified Fragment Length Polymorphism Analysis; Antineoplastic Agents, Phytogenic; Asian People; Camptothecin; Diarrhea; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Leukopenia; Middle Aged; Neutropenia; Ovarian Neoplasms; Polymorphism, Genetic; Promoter Regions, Genetic; Uterine Cervical Neoplasms | 2011 |
Adjuvant chemotherapy for stage I clear cell carcinoma of the ovary: an analysis of fully staged patients.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Female; Follow-Up Studies; Humans; Irinotecan; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Postoperative Care; Prognosis; Retrospective Studies; Survival Rate; Taxoids | 2012 |
Retrospective study comparing irinotecan and pegylated liposomal doxorubicin in treatment of recurrent platinum-refractory/resistant epithelial ovarian cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Female; Hand-Foot Syndrome; Humans; Irinotecan; Kaplan-Meier Estimate; Middle Aged; Mucositis; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum; Polyethylene Glycols; Retrospective Studies; Salvage Therapy | 2012 |
Long-term survival in patients with clear cell adenocarcinoma of ovary treated with irinotecan hydrochloride plus cisplatin therapy as first-line chemotherapy.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Cisplatin; Female; Humans; Irinotecan; Japan; Laparotomy; Middle Aged; Ovarian Neoplasms; Proportional Hazards Models; Retrospective Studies; Second-Look Surgery | 2012 |
The role of natural killer cells in combinatorial anti-cancer therapy using Sindbis viral vectors and irinotecan.
Topics: Animals; Camptothecin; Female; Humans; Irinotecan; Killer Cells, Natural; Mice; Mice, SCID; Neoplasms, Experimental; Oncolytic Virotherapy; Oncolytic Viruses; Ovarian Neoplasms; Sindbis Virus; Topoisomerase Inhibitors | 2012 |
Normal serum CA125 half-life and normal serum nadir CA125 level in patients with ovarian cancers.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-125 Antigen; Camptothecin; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Cyclophosphamide; Docetaxel; Doxorubicin; Etoposide; Female; Half-Life; Humans; Irinotecan; Linear Models; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Reference Values; Remission Induction; Taxoids | 2012 |
PEGylated liposome IHL-305 markedly improved the survival of ovarian cancer peritoneal metastasis in mouse.
Topics: Animals; Antineoplastic Agents; Ascites; Camptothecin; Cell Line, Tumor; Drug Delivery Systems; ErbB Receptors; Female; Humans; Irinotecan; Liposomes; Mice; Ovarian Neoplasms; Peritoneal Neoplasms; Polyethylene Glycols; Xenograft Model Antitumor Assays | 2012 |
Novel camptothecin derivative BNP1350 in experimental human ovarian cancer: determination of efficacy and possible mechanisms of resistance.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; Cell Division; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Irinotecan; Mice; Mice, Nude; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Neoplasm Transplantation; Ovarian Neoplasms; Topoisomerase I Inhibitors; Topotecan; Transplantation, Heterologous; Tumor Cells, Cultured | 2002 |
[A case of ovarian cancer in which a remarkable effect was seen with low-dose CDDP intratumoral injection of CPT-11].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cisplatin; Cystadenocarcinoma, Papillary; Drug Therapy, Combination; Female; Humans; Injections, Intralesional; Injections, Intravenous; Irinotecan; Middle Aged; Ovarian Neoplasms; Peritonitis | 2002 |
Establishment and characterization of a cell-line originated from human mucinous cystadenocarcinoma of the ovary.
Topics: Animals; Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Agents; Biomarkers, Tumor; Camptothecin; Cell Culture Techniques; Cell Division; Cisplatin; Cystadenocarcinoma, Mucinous; Drug Screening Assays, Antitumor; Female; Humans; Irinotecan; Karyotyping; Mice; Mice, Nude; Middle Aged; Neoplasm Transplantation; Ovarian Neoplasms; Tumor Cells, Cultured | 2002 |
Salvage chemotherapy with a combination of irinotecan hydrochloride and mitomycin C in platinum- and paclitaxel-resistant epithelial ovarian cancer: case reports.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Camptothecin; Carcinoma; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Irinotecan; Middle Aged; Mitomycin; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prognosis; Salvage Therapy; Sampling Studies; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome | 2003 |
Platinum retreatment of platinum-resistant ovarian cancer after nonplatinum therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Cyclophosphamide; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Middle Aged; Ovarian Neoplasms; Retrospective Studies | 2003 |
Apoptotic pathways of epothilone BMS 310705.
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Caspases; Cytochrome c Group; Drug Resistance, Neoplasm; Enzyme Activation; Epothilones; Female; Humans; Irinotecan; Isoenzymes; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Topotecan; Tumor Cells, Cultured | 2003 |
[Two patients with metastatic ovarian tumor (Krukenberg's tumor) of gastric origin who underwent oophorectomy with paraaortic and intrapelvic lymph node dissection].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Aorta; Camptothecin; Carcinoma, Signet Ring Cell; Cisplatin; Combined Modality Therapy; Female; Fluorouracil; Gastrectomy; Humans; Irinotecan; Krukenberg Tumor; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Ovarian Neoplasms; Ovariectomy; Stomach Neoplasms | 2003 |
[A case of gastric carcinoma with multiple skin, bone, and bilateral ovary metastasis; effective treatment by chemotherapy].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Cisplatin; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Ovarian Neoplasms; Prognosis; Quality of Life; Skin Neoplasms; Stomach Neoplasms | 2003 |
Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents.
Topics: Antineoplastic Agents; Camptothecin; Cell Division; Cell Line, Tumor; Colonic Neoplasms; Female; Fluorouracil; HCT116 Cells; Humans; Irinotecan; Models, Biological; Ovarian Neoplasms; Paclitaxel | 2004 |
Drug sensitivity-related benefit of systematic lymphadenectomy during cytoreductive surgery in optimally debulked stages IIIc and IV ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Humans; Irinotecan; Lymph Node Excision; Middle Aged; Multivariate Analysis; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Retrospective Studies | 2004 |
Usefulness of collagen gel droplet embedded culture drug sensitivity testing in ovarian cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Culture Techniques; Cell Line, Tumor; Chemotherapy, Adjuvant; Cisplatin; Clinical Laboratory Techniques; Collagen; Disease Progression; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Female; Gels; Humans; Irinotecan; Middle Aged; Ovarian Neoplasms; Paclitaxel; Pharmaceutical Preparations; Recurrence; Remission Induction; Sensitivity and Specificity; Time Factors; Treatment Outcome | 2004 |
UGT1A1*28 polymorphism in ovarian cancer patients.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Estrogens; Female; Glucuronosyltransferase; Heterozygote; Homozygote; Humans; Irinotecan; Loss of Heterozygosity; Odds Ratio; Ovarian Neoplasms; Polymerase Chain Reaction; Polymorphism, Genetic; Protein Isoforms; Regression Analysis | 2004 |
Complete response to irinotecan hydrochloride and nedaplatin in a patient with advanced ovarian clear cell carcinoma.
Topics: Adenocarcinoma, Clear Cell; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Humans; Irinotecan; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Parity; Treatment Outcome | 2004 |
Adenoviral vector-mediated expression of a gene encoding secreted, EpCAM-targeted carboxylesterase-2 sensitises colon cancer spheroids to CPT-11.
Topics: Adenoviridae; Antineoplastic Agents, Phytogenic; Camptothecin; Carboxylesterase; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Genetic Vectors; Humans; Irinotecan; Ovarian Neoplasms | 2005 |
[A case of advanced gastric cancer with lymphangitis carcinomatosa after operation of Krukenberg tumor treated by TS-1 plus CPT-11 as third-line chemotherapy].
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Combinations; Female; Humans; Irinotecan; Krukenberg Tumor; Lymphangitis; Ovarian Neoplasms; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur | 2005 |
Novel fluoro-substituted camptothecins: in vivo antitumor activity, reduced gastrointestinal toxicity and pharmacokinetic characterization.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; Female; Gastrointestinal Tract; Humans; Irinotecan; Male; Mammary Neoplasms, Experimental; Mice; Mice, Inbred C3H; Mice, Nude; Ovarian Neoplasms; Prodrugs; Rats; Rats, Sprague-Dawley; Tumor Burden; Xenograft Model Antitumor Assays | 2006 |
The safety and efficacy of the weekly dosing of irinotecan for platinum- and taxanes-resistant epithelial ovarian cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Retrospective Studies; Taxoids | 2006 |
Expression of drug pathway proteins is independent of tumour type.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Breast Neoplasms; Camptothecin; Colonic Neoplasms; Cytochrome P-450 Enzyme System; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Immunohistochemistry; Irinotecan; Lung Neoplasms; Lymphoma; Male; Melanoma; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Neoplasms; Ovarian Neoplasms; Prostatic Neoplasms; Tissue Array Analysis | 2006 |
[Colonic perforation in a patient treated with combination chemotherapy for recurrent ovarian clear cell adenocarcinoma].
Topics: Adenocarcinoma, Clear Cell; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cecal Diseases; Cisplatin; Colonoscopy; Drainage; Drug Administration Schedule; Fatal Outcome; Female; Humans; Intestinal Perforation; Irinotecan; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Pleural Effusion, Malignant | 2006 |
Adjuvant chemotherapy with irinotecan hydrochloride and cisplatin for clear cell carcinoma of the ovary.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Female; Gynecologic Surgical Procedures; Humans; Irinotecan; Middle Aged; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Prognosis; Retrospective Studies; Survival Analysis; Treatment Outcome | 2006 |
Thrombotic microangiopathy and anti-VEGF agents.
Topics: Biopsy; Camptothecin; Drug Therapy, Combination; Female; Humans; Irinotecan; Kidney Glomerulus; Middle Aged; Ovarian Neoplasms; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Thrombosis; Vascular Endothelial Growth Factor A | 2007 |
[A recurrent ovarian cancer patient who achieved a complete response following irinotecan plus CDDP therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bridged-Ring Compounds; CA-125 Antigen; Camptothecin; Carcinoma, Endometrioid; Cisplatin; Drug Administration Routes; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Laparotomy; Ovarian Neoplasms; Paclitaxel; Remission Induction; Taxoids | 2007 |
[Outpatient chemotherapy in gynecologic oncology].
Topics: Ambulatory Care Facilities; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Combined Modality Therapy; Doxorubicin; Drug Administration Schedule; Female; Humans; Irinotecan; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Uterine Cervical Neoplasms; Uterine Neoplasms | 2006 |
Progression-free survival and overall survival of patients with clear cell carcinoma of the ovary treated with paclitaxel-carboplatin or irinotecan-cisplatin: retrospective analysis.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Female; Humans; Irinotecan; Middle Aged; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Survival Analysis | 2007 |
Carbon beam therapy in recurrent ovarian cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carbon; Carboplatin; Carcinoma, Endometrioid; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Hysterectomy; Irinotecan; Lymph Node Excision; Neoplasm Recurrence, Local; Omentum; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Radiotherapy, High-Energy; Remission Induction; Salvage Therapy | 2008 |
[Multiple hepatic metastases and ovarian metastases of colon cancer responding to combined therapy with S-1 and CPT-11--a case report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug Combinations; Female; Humans; Irinotecan; Liver Neoplasms; Middle Aged; Ovarian Neoplasms; Oxonic Acid; Tegafur; Tomography, X-Ray Computed | 2008 |
Irinotecan HCl, an anticancer topoisomerase I inhibitor, frequently induces ovarian failure in premenopausal and perimenopausal women.
Topics: Adult; Antineoplastic Agents, Phytogenic; Camptothecin; Enzyme Inhibitors; Female; Humans; Irinotecan; Middle Aged; Ovarian Neoplasms; Ovary; Perimenopause; Premenopause; Primary Ovarian Insufficiency; Treatment Outcome; Uterine Cervical Neoplasms | 2008 |
Intracellular accumulation and DNA damage persistence as determinants of human squamous cell carcinoma hypersensitivity to the novel camptothecin ST1968.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Carcinoma, Squamous Cell; Caspase 3; DNA Damage; Drug Evaluation; Female; Humans; Irinotecan; Male; Mice; Mice, Nude; Neoplasm Transplantation; Ovarian Neoplasms; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Prostatic Neoplasms; Transplantation, Heterologous; Tumor Cells, Cultured | 2008 |
Metabolism of irinotecan to SN-38 in a tissue-isolated tumor model.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma 256, Walker; Cattle; Chromatography, High Pressure Liquid; Female; Irinotecan; Ovarian Neoplasms; Rats; Rats, Wistar; Tumor Cells, Cultured | 1995 |
Intracellular carboxyl esterase activity is a determinant of cellular sensitivity to the antineoplastic agent KW-2189 in cell lines resistant to cisplatin and CPT-11.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Carboxylic Ester Hydrolases; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; DNA; Drug Resistance; Drug Resistance, Multiple; Duocarmycins; Female; Humans; Irinotecan; Lung Neoplasms; Microsomes; Ovarian Neoplasms; Pyrrolidinones; Tumor Cells, Cultured | 1995 |
[Combination therapy with irinotecan and CBDCA for patients in terminal stage of ovarian carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cystadenocarcinoma, Serous; Drug Administration Schedule; Female; Humans; Irinotecan; Leukopenia; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Thrombocytopenia | 1996 |
Interleukin-1 alpha-induced modulation of topoisomerase I activity and DNA damage: implications in the mechanisms of synergy with camptothecins in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Biological Transport; Blotting, Western; Breast Neoplasms; Camptothecin; Cell Nucleus; Cell Survival; DNA Damage; DNA Topoisomerases, Type I; Drug Administration Schedule; Drug Synergism; Electrophoresis, Polyacrylamide Gel; Female; Humans; Interleukin-1; Irinotecan; Mice; Mice, Nude; Nuclear Proteins; Ovarian Neoplasms; Protein Biosynthesis; Recombinant Proteins; Transcription, Genetic; Transplantation, Heterologous | 1996 |
[The results of chemosensitivity test for clear cell adenocarcinoma of the ovary].
Topics: Adenocarcinoma, Clear Cell; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Doxorubicin; Drug Screening Assays, Antitumor; Etoposide; Female; Humans; Irinotecan; Mitomycin; Ovarian Neoplasms | 1996 |
Anti-tumor activity of CPT-11 in experimental human ovarian cancer and human soft-tissue sarcoma.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; DNA Topoisomerases, Type I; Drug Screening Assays, Antitumor; Female; Humans; Injections, Intraperitoneal; Injections, Intravenous; Irinotecan; Mice; Mice, Nude; Neoplasm Transplantation; Ovarian Neoplasms; RNA, Messenger; Sarcoma; Sarcoma, Experimental; Tumor Cells, Cultured | 1997 |
[Derivatives of camptothecin. A new class of antineoplastic agents].
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Female; Humans; Irinotecan; Ovarian Neoplasms; Topotecan | 1997 |
[Evaluation of a new anti-cancer drug regimen for surface epithelial-stromal ovarian cancer].
Topics: Adenoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Cyclophosphamide; Cystadenocarcinoma, Serous; Doxorubicin; Female; Humans; Irinotecan; Mice; Mice, Inbred BALB C; Mice, Inbred ICR; Mice, Nude; Neoplasm Transplantation; Ovarian Neoplasms; Paclitaxel; Tumor Cells, Cultured | 1998 |
Reduced cellular accumulation of topotecan: a novel mechanism of resistance in a human ovarian cancer cell line.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Camptothecin; Cell Line; Cross Reactions; Drug Resistance; Enzyme Inhibitors; Female; Glucose; Humans; Irinotecan; Kinetics; Ovarian Neoplasms; Temperature; Topoisomerase I Inhibitors; Topotecan | 1998 |
Induction of p53-dependent and p53-independent cellular responses by topoisomerase 1 inhibitors.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Cycle; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Female; Flow Cytometry; Genes, p53; Humans; Irinotecan; Ovarian Neoplasms; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured; Tumor Stem Cell Assay; Tumor Suppressor Protein p53 | 1998 |
In vitro sensitivity of fresh ovarian carcinoma specimens to CPT-11 (irinotecan).
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Camptothecin; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Flow Cytometry; Humans; In Vitro Techniques; Irinotecan; Ovarian Neoplasms; Topoisomerase I Inhibitors | 1999 |
Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line.
Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; Drug Resistance, Multiple; Female; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Kinetics; Mitoxantrone; Neoplasm Proteins; Ovarian Neoplasms; Topotecan; Tumor Cells, Cultured | 1999 |
Topoisomerase-I activity and response to second-line chemotherapy consisting of camptothecin-11 and cisplatin in patients with ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Middle Aged; Ovarian Neoplasms | 1999 |
New highly lipophilic camptothecin BNP1350 is an effective drug in experimental human cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Colonic Neoplasms; Doxorubicin; Drug Resistance, Multiple; Enzyme Inhibitors; Female; Humans; Irinotecan; Lung Neoplasms; Melanoma; Mice; Mice, Nude; Neoplasms; Ovarian Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2000 |
Irinotecan: a new agent comes of age.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Female; Gastrointestinal Neoplasms; Humans; International Cooperation; Irinotecan; Male; Ovarian Neoplasms; Uterine Cervical Neoplasms | 2001 |
Transport of topoisomerase I inhibitors by the breast cancer resistance protein. Potential clinical implications.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Camptothecin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Irinotecan; Mice; Mice, Inbred BALB C; Mitoxantrone; Neoplasm Proteins; Ovarian Neoplasms; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured | 2000 |
[A case of papillary adenocarcinoma of the ovary that responded favorably to irinotecan hydrochloride and cisplatin after the administration of paclitaxel and carboplatin].
Topics: Adenocarcinoma, Papillary; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Carboplatin; Cisplatin; Cyclophosphamide; Female; Humans; Irinotecan; Middle Aged; Ovarian Neoplasms; Paclitaxel; Treatment Outcome | 2001 |
Paclitaxel and SN-38 overcome cisplatin resistance of ovarian cancer cell lines by down-regulating the influx and efflux system of cisplatin.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Camptothecin; Cell Division; Cisplatin; DNA-Binding Proteins; Dose-Response Relationship, Drug; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Irinotecan; Multidrug Resistance-Associated Proteins; MutS Homolog 3 Protein; Ouabain; Ovarian Neoplasms; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Time Factors; Tumor Cells, Cultured | 2001 |
Malignant mixed mesodermal tumor of the ovary treated with a cisplatin-irinotecan combination: case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Enzyme Inhibitors; Female; Humans; Irinotecan; Middle Aged; Mixed Tumor, Mesodermal; Ovarian Neoplasms; Remission Induction; Topoisomerase I Inhibitors | 2001 |
[Globalization of anti-cancer therapies].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carboplatin; Cisplatin; Colorectal Neoplasms; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Neoplasms; Ovarian Neoplasms; Paclitaxel; Prostatic Neoplasms; Stomach Neoplasms | 2002 |
[Apoptosis as a measure of chemosensitivity to anti-cancer drugs in gynecological cancer].
Topics: Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Cisplatin; Drug Screening Assays, Antitumor; Female; Humans; In Situ Nick-End Labeling; Irinotecan; Mice; Mice, Nude; Mitomycin; Neoplasm Transplantation; Ovarian Neoplasms; Paclitaxel; Tumor Cells, Cultured; Uterine Neoplasms | 2002 |
[A case of advanced ovarian carcinosarcoma that responded remarkably to neoadjuvant chemotherapy of combined CPT-11 and CDDP].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinosarcoma; Cisplatin; Drug Administration Schedule; Female; Humans; Hysterotomy; Irinotecan; Lymph Node Excision; Middle Aged; Neoadjuvant Therapy; Ovarian Neoplasms | 2002 |
Factors influencing the cellular accumulation of SN-38 and camptothecin.
Topics: Adenocarcinoma; Biological Transport; Camptothecin; Colonic Neoplasms; Drug Resistance, Multiple; Enzyme Inhibitors; Female; Genes, MDR; Humans; Irinotecan; Kinetics; Membrane Transport Proteins; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Ovarian Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Time Factors; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 2002 |
Overexpression of PTEN increases sensitivity to SN-38, an active metabolite of the topoisomerase I inhibitor irinotecan, in ovarian cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Division; DNA Topoisomerases, Type I; Female; Gene Expression; Genetic Vectors; Humans; Inhibitory Concentration 50; Irinotecan; Ovarian Neoplasms; Phosphoric Monoester Hydrolases; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Sequence Analysis, DNA; Topoisomerase I Inhibitors; Transfection; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2002 |
Sensitivity to anticancer agents and resistance mechanisms in clear cell carcinoma of the ovary.
Topics: Adenocarcinoma, Clear Cell; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B, Member 1; Camptothecin; Cisplatin; Coloring Agents; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Etoposide; Female; Glutathione; Humans; Inhibitory Concentration 50; Irinotecan; Mitochondrial Proteins; Mitomycin; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Ovarian Neoplasms; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; Ribosomal Proteins; RNA, Messenger; Saccharomyces cerevisiae Proteins; Tetrazolium Salts; Thiazoles; Tumor Cells, Cultured | 2002 |
Irinotecan pharmacokinetics-pharmacodynamics: the clinical relevance of prolonged exposure to SN-38.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Colonic Neoplasms; Colorectal Neoplasms; Drug Administration Schedule; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Ovarian Neoplasms; Prodrugs; Random Allocation; Tumor Cells, Cultured; Uterine Cervical Neoplasms | 2002 |
Mechanism of cross-resistance to a camptothecin analogue (CPT-11) in a human ovarian cancer cell line selected by cisplatin.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Camptothecin; Cisplatin; DNA Topoisomerases, Type I; Drug Resistance; Female; Gene Expression; Genes, myc; Glutathione; Glutathione Transferase; Humans; In Vitro Techniques; Irinotecan; Membrane Glycoproteins; Ovarian Neoplasms; RNA, Messenger; RNA, Neoplasm; Tumor Cells, Cultured | 1992 |
[Preclinical evaluation of a new camptothecin derivative, CPT-11, on the subrenal capsule assay].
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Colony-Forming Units Assay; Drug Evaluation, Preclinical; Female; Irinotecan; Ovarian Neoplasms; Tumor Stem Cell Assay | 1987 |